New peptidic non-covalent direct thrombin inhibitors (DTIs) were designed by generating peptide lead compounds derived from the substrate sequence Phe(P3)-Pro(P2)-Arg(P1). The free energy of interaction between each ligand and thrombin was calculated with the built-in molecular mechanics force field (MMFF) provided by the docking software SCULPT (Accelrys). During the original screening, the hexapeptides [D-Phe(P3)-Pro(P2)-D-Arg(P1)-P1�-P2�-P3�-CONH2] and pentapeptides [D-Phe(P3)-Pro(P2)-D-Arg(P1)-P1�-P2�-CONH2] were used as scaffolds for developing the optimized final tetrapeptide lead sequence, D-Phe(P3)-Pro(P2)-D-Arg(P1)-P1�-CONH2. Once the lead tetrapeptide scaffold was found to have higher affinity for thrombin than the hexa and pentapeptides, based on structure-activity relationship (SAR) studies on thrombin inhibition conducted in vitro, new peptide candidate inhibitors were further designed as derivatives of the tetrapeptide motif D-Phe(P3)-Pro(P2)-D-Arg(P1)-P1�-CONH2. Trials for optimization of P3 position were further performed with nonnatural amino-acids, such as D-3,3-di-Phenylalanine, trans and dihydrocinnamic acids, (L)/(D)-Tic [1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid], (L)/(D)-Thi [Thienylalanine] and D-Naphthylalanine (D-Nal). The thrombin:peptide complex was minimized using the SCULPT built-in molecular mechanics force field (MMFF94). After each round of minimization, the free energy of interaction (scoring function) was assessed using both Van der Waals and electrostatic force fields.  Preliminary kinetics for in vitro inhibition of alpha thrombin cleavage of the chromogenic substrate S2238 established a new structure-activity relationship (SAR) for the tetrapeptides with new unnatural aminoacids at (P3) position.

Molecular docking, in silico structure-based design, and kinetic evaluation of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.